Drug products: ADARTREL, Requip, Requip Depot, Requip®, Ropinirol 2care4, Ropinirol Ebb, Ropinirol Krka, Ropinirol Mylan, Ropinirol Sandoz, Ropinirol Stada, Ropinirole Orifarm, Ropinirole Teva
ATC code: N04BC04
Substances: ropinirole, ropinirole hydrochloride
The main indication of ropinirol is treatment for Parkinson Disease but the drug is also used in Restless Legs Syndrome (RLS). Clinical studies have shown ropinirol up to 4 mg/day have no exposure related effects on the mean of QT interval in healthy men and women.
Clinical studies have shown that oral doses as low as 0.2 mg suppressed serum prolactin concentration in healthy men.
In our opinion, the described differences do not motivate differentiated dosing or treatment in men and women.
Oral clearance of ropinirol have shown to be similar in men and women . Ropinirol is indicated for treatment of Parkinson’s disease and for treatment of Restless Legs Syndrome. Therapy with ropinirol is initiated at a low dose and gradually titrated upward according to clinical tolerability to obtain the optimum therapeutic effect. It is not necessary to adjust the initial dose based on sex .
No studies with a clinically relevant sex analysis regarding the effects of ropinirol have been found .
Ropinirol have shown to have no dose- or exposure-related effect on mean QT intervals in healthy men and women titrated to doses up to 4 mg/day .
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
At oral doses as low as 0.2 mg, ropinirol suppressed serum prolactin concentrations in healthy men .
Date of litterature search: 2013-04-02
Reviewed by: Expertrådet för neurologiska sjukdomar
Approved by: Mia von Euler